Shortest possible acceptable effective chemotherapy in ambulatory patients with pulmonary tuberculosis. Part II. Results during the 24 months after the end of chemotherapy.
Efficacy of two 4.5-month regimens (3 RSZH / S2H2Z2 and 3 RSZH /RH) and one 3-month regimen (3 RSZH ) in the management of pulmonary tuberculosis is reported (see table 1 for definition of regimen abbreviations). Even when the patients were ambulatory and outpatient attendance was required for supervised drug administration, drug compliance was high (87%). Bacillary sterilization was achieved in 99% of the patients at 3 months. During first year follow-up after cessation of chemotherapy, 6% of the patients receiving the 3 RSZH regimen, 7% of the patients receiving the 3 RSZH / S2H2Z2 regimen, and 2% of the patients receiving the 3 RSZH / R2H2 regimen experienced relapse. During second year follow-up, relapse was observed in only 1 patient receiving the 3 RSZH / S2H2Z2 regimen. The patients who relapsed usually had drug-susceptible strains at the time of relapse. Regression of pulmonary lesions continued even after the cessation of chemotherapy.
D000553:Ambulatory Care; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005000:Ethionamide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D007538:Isoniazid / Q000008:administration & dosage; D010349:Patient Compliance; D011718:Pyrazinamide / Q000008:administration & dosage; D011897:Random Allocation; D012293:Rifampin / Q000008:administration & dosage; D013307:Streptomycin / Q000008:administration & dosage; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin